TABLE III.

Individual data of 21 patients infected by SARS-CoV-2 during the study time

Period	Sex	Age range (y)	Lymphocytes (cell/mm3)	CD4+ count (cell/mm3)	Immunoglobulin defect	Risk factors for severe COVID-19	Dose(s) of vaccine at SARS-CoV-2 infection	COVID-19 course	Treatment	Days of qRT-PCR positivity	Outcome	Cardiological outcome
Preimmunization	M	50–29	1,000	380	IgG	DMT2, obesity, kidney failure, mood disorders	None	Severe (ARDS)	Oxygen therapy, dialysis	NAp	Death	NAp
Preimmunization	F	20–29	1,290	438	No	Developmental disabilities, schizophrenia spectrum disorders	None	Mild	None	21	Recovery	No echocardiographic or ECG changes
Preimmunization	F	40–49	1,500	580	No		None	Mild	Antibiotic	10	Recovery	No echocardiographic or ECG changes
Post-full immunization	M	20–29	820	190	No	Corrected subaortic VSD, multiple VSDs in natural hystory, schizophrenia spectrum disorders, developmental disabilities	2 doses	Asymptomatic	None	10	Recovery	No echocardiographic or ECG changes
Post-full immunization	F	30–39	1,230	488	IgG, IgM, and IgA defect	Corrected ToF, overweight, dyslipidemic, developmental disabilities, schizophrenia spectrum disorders	2 doses	Mild	None	10	Recovery	NA
Post-full immunization	F	20–20	1,810	NA	No	Small subaortic VSD in natural history	2 doses	Mild	NSAID	17	Recovery	No echocardiographic or ECG changes
Post-full immunization	M	30–39	1,180	400	No	Small subaortic VSD in natural history, overweight, schizophrenia spectrum disorders	2 doses	Mild	None	39	Recovery	No echocardiographic or ECG changes, arterial hypertension diagnosis
Post-full immunization	F	40–49	760	270	IgG	Obesity, developmental disabilities, schizophrenia spectrum disorders	2 doses	Mild	None	16	Recovery	No echocardiographic or ECG changes
Post-full immunization	F	20–29	1,690	662	No	Developmental disabilities,	2 doses	Mild	None	31	Recovery	No echocardiographic or ECG changes
Post-booster dose	F	30–39	900	390	No	Developmental disabilities	3 doses	Mild	Paxlovid	10	Recovery	No echocardiographic or ECG changes
Post-booster dose	F	18–19	1,755	720	No	Overweight, developmental disabilities, mood disorders	3 doses	Mild	None	10	Recovery	No echocardiographic or ECG changes
Post-booster dose	M	20–29	1,180	554	No	Corrected ToF, overweight, developmental disabilities, schizophrenia spectrum disorders	3 doses	Asymptomatic	None	10	Recovery	No echocardiographic or ECG changes
Post-booster dose	F	20–29	1,000	400	No	Obesity, developmental disabilities, schizophrenia spectrum disorders	3 doses	Asymptomatic	Sotrovimab	7	Recovery	No echocardiographic or ECG changes
Post-booster dose	M	30–29	2,030	875	No	Overweight, developmental disabilities, schizophrenia spectrum disorders	3 doses	Mild	None	13	Recovery	No echocardiographic or ECG changes
Post-booster dose	M	20–29	2,600	1,089	IgM defect	Corrected IAA, overweight, developmental disabilities	3 doses	Mild	Sotrovimab	7	Recovery	NA
Post-booster dose	F	20–29	1,131	585	IgG/IgA defect	Corrected ToF, corticosteroid medications	3 doses	Mild	Molnupiravir	10	Recovery	Hypertension during infection. No echocardiographic or ECG changes
Post-booster dose	M	50–59	1,650	650	IgM defect	Corrected hemitruncus, DMT2, obesity	4 doses	Mild	None (refused)	63	Recovery	No echocardiographic or ECG changes
Post-booster dose	M	20–29	1,530	NA	No	Obesity, developmental disabilities, schizophrenia spectrum disorders	3 doses	Mild	Sotrovimab	15	Recovery	NA
Post-booster dose	M	30–39	3,700	NA	No	Obesity	3 doses	Mild	Paxlovid	7	Recovery	NA
Post-booster dose	M	20–29	2,340	550	No	Developmental disabilities, schizophrenia spectrum disorders	3 doses	Mild	None	NA	Recovery	No echocardiographic or ECG changes
Post-booster dose	M	20–29	1,500	NA	No	Developmental disabilities, schizophrenia spectrum disorders	3 doses	Mild	Molnupiravir	10	Recovery	NA
Post-booster dose	F	20–29	1,000	400	No	Obesity, developmental disabilities, schizophrenia spectrum disorders	3 doses	Mild	Antibiotic	10	Recovery	No echocardiographic or ECG changes

ARDS, Adult respiratory distress syndrome; DMT2, diabetes mellitus type 2; ECG electrocardiogram; IAA, interrupted aortic arch; NA, not available; NAp, not applicable; NSAIDs, nonsteroidal anti-inflammatory drugs; qRT-PCR, quantitative reverse transcriptase–polymerase chain reaction.